SK11522000A3 - Farmaceutický prípravok obsahujúci agonistu receptora angiotenzínu ii typu 2 a jeho použitie - Google Patents

Farmaceutický prípravok obsahujúci agonistu receptora angiotenzínu ii typu 2 a jeho použitie Download PDF

Info

Publication number
SK11522000A3
SK11522000A3 SK1152-2000A SK11522000A SK11522000A3 SK 11522000 A3 SK11522000 A3 SK 11522000A3 SK 11522000 A SK11522000 A SK 11522000A SK 11522000 A3 SK11522000 A3 SK 11522000A3
Authority
SK
Slovakia
Prior art keywords
agonist
angiotensin
receptor
type
selective
Prior art date
Application number
SK1152-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Lars F�NDRIKS
Anders Pettersson
Anders Hallberg
Original Assignee
A+ Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A+ Science Invest Ab filed Critical A+ Science Invest Ab
Publication of SK11522000A3 publication Critical patent/SK11522000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1152-2000A 1998-02-24 1999-02-24 Farmaceutický prípravok obsahujúci agonistu receptora angiotenzínu ii typu 2 a jeho použitie SK11522000A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9800550A SE9800550D0 (sv) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
PCT/SE1999/000262 WO1999043339A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof

Publications (1)

Publication Number Publication Date
SK11522000A3 true SK11522000A3 (sk) 2001-04-09

Family

ID=20410283

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1152-2000A SK11522000A3 (sk) 1998-02-24 1999-02-24 Farmaceutický prípravok obsahujúci agonistu receptora angiotenzínu ii typu 2 a jeho použitie

Country Status (18)

Country Link
EP (1) EP1066048A1 (no)
JP (1) JP2002504516A (no)
KR (1) KR20010041211A (no)
CN (1) CN1291104A (no)
AU (1) AU755949B2 (no)
BR (1) BR9908188A (no)
CA (1) CA2319123A1 (no)
EE (1) EE200000481A (no)
HU (1) HUP0101411A3 (no)
ID (1) ID26639A (no)
IL (1) IL137990A0 (no)
IS (1) IS5594A (no)
MX (1) MXPA00008172A (no)
NO (1) NO20004215L (no)
NZ (1) NZ506188A (no)
SE (1) SE9800550D0 (no)
SK (1) SK11522000A3 (no)
WO (1) WO1999043339A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043761A2 (en) * 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
ATE372987T1 (de) 2001-05-31 2007-09-15 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
CN101193886B (zh) 2005-04-12 2014-08-27 维科尔药物公司 三环的血管紧张素ii激动剂
EP1869024B1 (en) 2005-04-12 2010-11-10 Vicore Pharma AB New tricyclic angiotensin ii agonists
ES2582945T3 (es) 2005-04-12 2016-09-16 Vicore Pharma Ab Nuevos agonistas bicíclicos de angiotensina II
CA2631491C (en) * 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
US20150119329A1 (en) * 2012-04-16 2015-04-30 New York University Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral
WO2016139475A1 (en) 2015-03-02 2016-09-09 Vicore Pharma Ab Angiotensin ii receptor agonist for treating pulmonary fibrosis
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
CN114514032A (zh) 2019-08-02 2022-05-17 兰提欧派普有限公司 用于治疗癌症的血管紧张素2型(at2)受体激动剂
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
JP2023518948A (ja) 2020-03-19 2023-05-09 ヴィコール ファルマ アーベー アンギオテンシンｉｉに関連する疾患、障害又は状態の治療及び／又は予防に有用な新規化合物
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006081D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
JP2024511453A (ja) 2021-03-23 2024-03-13 ヴィコール ファルマ アーベー 選択的アンジオテンシンｉｉ受容体リガンド
CA3222721A1 (en) 2021-07-09 2023-01-12 Nadia Nasser PETERSEN New selective angiotensin ii compounds
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444067A (en) * 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
AU3708295A (en) * 1994-11-04 1996-05-31 Stefan L. Marklund Use of receptor agonists to stimulate superoxide dismutase activity
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
US5834432A (en) * 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (sv) * 1995-06-19 1995-06-19 Astra Ab Novel medical use

Also Published As

Publication number Publication date
CA2319123A1 (en) 1999-09-02
BR9908188A (pt) 2000-10-24
AU755949B2 (en) 2003-01-02
EE200000481A (et) 2002-02-15
MXPA00008172A (es) 2002-06-21
KR20010041211A (ko) 2001-05-15
NO20004215L (no) 2000-09-18
EP1066048A1 (en) 2001-01-10
IL137990A0 (en) 2001-10-31
NO20004215D0 (no) 2000-08-23
WO1999043339A1 (en) 1999-09-02
NZ506188A (en) 2003-04-29
ID26639A (id) 2001-01-25
SE9800550D0 (sv) 1998-02-24
IS5594A (is) 2000-08-21
AU2753799A (en) 1999-09-15
JP2002504516A (ja) 2002-02-12
CN1291104A (zh) 2001-04-11
HUP0101411A3 (en) 2002-11-28
HUP0101411A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
SK11522000A3 (sk) Farmaceutický prípravok obsahujúci agonistu receptora angiotenzínu ii typu 2 a jeho použitie
EP1789067B1 (en) Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
Hernandez et al. Prevention of stress-induced gastric ulcers by dopamine agonists in the rat
Tytgat Colloidal bismuth subcitrate in peptic ulcer-a review
RU2345790C2 (ru) Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда
CA2444876A1 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
Kato et al. Role of peripheral capsaicin-sensitive neurons and CGRP in central vagally mediated gastroprotective effect of TRH
US6020305A (en) Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors
EP0840607B1 (en) Novel medical use
Leslie et al. Absence of blood-pressure lowering effect of captopril in anephric patients.
Griffing et al. The therapeutic use of a new potassium-sparing diuretic, amiloride, and a converting enzyme inhibitor, MK-421, in preventing hypokalemia associated with primary and secondary hyperaldosteronism
US6204271B1 (en) Analgesic composition and method for using same
Waisman et al. Naloxone is protective against indomethacin-induced intestinal ulceration in the rat
CZ20003080A3 (cs) Farmaceutický prostředek obsahující agonistu receptoru pro angiotensin II 2.typu a jeho použití
Amagase et al. Possible mechanism of gastric mucosal protection by epidermal growth factor in rats
KR20050098831A (ko) 테나토프라졸 및 히스타민 ｈ2-수용체 길항제를 배합한제약 조성물
US4470974A (en) Gastric cytoprotection with L-363,586
Ajayi et al. Captopril and opiate antagonism in essential hypertension.
Hsu et al. Roles of in vitro-and in vivo-administered histamine and serotonin in compound 48/80-induced gastric acid secretion in isolated, perfused rat stomach
KR100197929B1 (ko) 고혈압 치료제 조성물
Konturek et al. Comparison of telenzepine, pirenzepine and atropine on gastric acid and pepsin secretion in response to histamine, pentagastrin, bethanechol, sham-feeding and feeding
Bazzani et al. Serotonin Is Involved in the ACTH-lnduced Reversal of Hemorrhagic Shock in Anesthetized Rats
MXPA97010002A (es) Nuevo uso medico
Walthall Angiotensin receptor blockers in hypertension and heart failure
Reidelberger PRASANTH K. CHELIKANI, ALVIN HAVER, AND ROGER D. REIDELBERGER